Literature DB >> 19622722

Cutaneous melanoma is related to immune suppression in kidney transplant recipients.

Claire M Vajdic1, Marina T van Leeuwen, Angela C Webster, Margaret R E McCredie, John H Stewart, Jeremy R Chapman, Janaki Amin, Stephen P McDonald, Andrew E Grulich.   

Abstract

Melanoma incidence is increased after organ transplantation, but there is uncertainty as to why this occurs. Diagnoses of invasive melanoma were ascertained in 8,152 kidney transplant recipients (1982-2003) by linking national Australian population-based registers, the Australia and New Zealand Dialysis and Transplant Registry, and the Australian National Cancer Statistics Clearing House. Incidence rate ratios (IRR) and standardized incidence ratios were used to compare melanoma risk during periods of transplant function and failure. Standardized incidence ratios were also computed by time since transplantation. Risk factors were examined using multivariate Poisson regression. Linkage identified 82 melanomas (134/100,000 person-years). Incidence was lower after resumption of dialysis and reduction of immune suppression than during transplant function [IRR, 0.09; 95% confidence interval (95% CI), 0.01-0.66]. During first transplant function, melanoma (n = 74) relative risk peaked in the second year and declined linearly thereafter (P trend = 0.03). During first transplant function, risk was positively associated with increasing year of age (IRR, 1.05; 95% CI, 1.03-1.07) and receipt of lymphocyte-depleting antibody (IRR, 1.73; 95% CI, 1.05-2.84). Female sex (IRR, 0.57; 95% CI, 0.35-0.94), non-Caucasian race (IRR, 0.15; 95% CI, 0.02-1.05), and increasing time since transplantation (P trend = 0.06) were inversely associated with risk. The incidence pattern and risk factor profile for melanoma after transplantation strongly suggest that the current receipt, intensity, and possibly the recency of iatrogenic immunosuppression increase melanoma risk. Melanoma risk was also associated with proxy indicators of high personal sun exposure and sensitivity. These findings show the marked influence of immunologic control over melanoma incidence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622722     DOI: 10.1158/1055-9965.EPI-09-0278

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

1.  An essential role for platelet-activating factor in activating mast cell migration following ultraviolet irradiation.

Authors:  Rommel Chacón-Salinas; Limo Chen; Alma D Chávez-Blanco; Alberto Y Limón-Flores; Ying Ma; Stephen E Ullrich
Journal:  J Leukoc Biol       Date:  2013-09-05       Impact factor: 4.962

2.  Melanoma survival in the United States, 1992 to 2005.

Authors:  Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

3.  Current status of immunotherapy for the treatment of lung cancer.

Authors:  Sanjay Murala; Vamsi Alli; Daniel Kreisel; Andrew E Gelman; Alexander S Krupnick
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

4.  Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas: A Retrospective Study of 53 Cases.

Authors:  Emilie Ducroux; Clemmie Martin; Jan Nico Bouwes Bavinck; Evelyne Decullier; Anabelle Brocard; Marlies E Westhuis-van Elsäcker; Céleste Lebbé; Camille Francès; Emmanuel Morelon; Christophe Legendre; Pascal Joly; Jean Kanitakis; Denis Jullien; Sylvie Euvrard; Jacques Dantal
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 5.  Management of patients with a failed kidney transplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy.

Authors:  Phuong-Thu Pham; Matthew Everly; Arman Faravardeh; Phuong-Chi Pham
Journal:  World J Nephrol       Date:  2015-05-06

Review 6.  Malignancy after renal transplantation: the role of immunosuppression.

Authors:  Inés Rama; Josep M Grinyó
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

Review 7.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

Review 8.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

9.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11

10.  Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.

Authors:  Marina T van Leeuwen; Claire M Vajdic; Melanie G Middleton; Ann M McDonald; Matthew Law; John M Kaldor; Andrew E Grulich
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.